Henk Visscher
Henk Visscher
Affiliation inconnue
Adresse e-mail validée de cmmt.ubc.ca
Citée par
Citée par
Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children
H Visscher, CJD Ross, SR Rassekh, A Barhdadi, MP Dubé, H Al-Saloos, ...
Journal of clinical oncology 30 (13), 1422-1428, 2012
Efflux and Atherosclerosis: The Clinical and Biochemical Impact of Variations in the ABCA1 Gene
RR Singaraja, LR Brunham, H Visscher, JJP Kastelein, MR Hayden
Arteriosclerosis, thrombosis, and vascular biology 23 (8), 1322-1332, 2003
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
CJD Ross, H Katzov-Eckert, MP Dubé, B Brooks, SR Rassekh, ...
Nature genetics 41 (12), 1345-1349, 2009
CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup
SC Warby, A Montpetit, AR Hayden, JB Carroll, SL Butland, H Visscher, ...
The American Journal of Human Genetics 84 (3), 351-366, 2009
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin
LR Brunham, PJ Lansberg, L Zhang, F Miao, C Carter, GK Hovingh, ...
The pharmacogenomics journal 12 (3), 233-237, 2012
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer
F Aminkeng, AP Bhavsar, H Visscher, SR Rassekh, Y Li, JW Lee, ...
Nature genetics 47 (9), 1079-1084, 2015
HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia
SC Warby, H Visscher, JA Collins, CN Doty, C Carter, SL Butland, ...
European Journal of Human Genetics 19 (5), 561-566, 2011
Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome
PJA de Pagter, R Schuurman, H Visscher, M de Vos, M Bierings, ...
Biology of Blood and Marrow Transplantation 14 (7), 831-839, 2008
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline‐induced cardiotoxicity in children
H Visscher, CJD Ross, SR Rassekh, GSS Sandor, HN Caron, ...
Pediatric blood & cancer 60 (8), 1375-1381, 2013
Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1
CL Wellington, LR Brunham, S Zhou, RR Singaraja, H Visscher, A Gelfer, ...
Journal of lipid research 44 (8), 1470-1480, 2003
Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin‐Induced Hearing Loss in Children
K Pussegoda, CJ Ross, H Visscher, M Yazdanpanah, B Brooks, ...
Clinical Pharmacology & Therapeutics 94 (2), 243-251, 2013
Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid phenotypes both in vivo and in vitro
RR Singaraja, H Visscher, ER James, A Chroni, JM Coutinho, ...
Circulation research 99 (4), 389-397, 2006
Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children
H Visscher, SR Rassekh, GS Sandor, HN Caron, EC Van Dalen, ...
Pharmacogenomics 16 (10), 1065-1076, 2015
The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology
CJD Ross, H Visscher, J Sistonen, LR Brunham, K Pussegoda, TT Loo, ...
Thyroid 20 (7), 681-687, 2010
Pharmacogenomics of serious adverse drug reactions in pediatric oncology
CJD Ross, H Visscher, SR Rassekh, LI Castro-Pastrana, E Shereck, ...
Journal of Population Therapeutics and Clinical Pharmacology 18 (1), 2011
Alternate transcripts expressed in response to diet reflect tissue-specific regulation of ABCA1
RR Singaraja, ER James, J Crim, H Visscher, A Chatterjee, MR Hayden
Journal of lipid research 46 (10), 2061-2071, 2005
Application of principal component analysis to pharmacogenomic studies in Canada
H Visscher, CJD Ross, MP Dube, AMK Brown, MS Phillips, BC Carleton, ...
The pharmacogenomics journal 9 (6), 362-372, 2009
Pharmacogenomics of vincristine‐induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes
GEB Wright, U Amstutz, BI Drögemöller, J Shih, SR Rassekh, MR Hayden, ...
Clinical Pharmacology & Therapeutics 105 (2), 402-410, 2019
Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.
BC Carleton, CJ Ross, AP Bhavsar, U Amstutz, K Pussegoda, H Visscher, ...
Clinical pharmacology and therapeutics 95 (3), 253-253, 2013
The influence of genetic variation on late toxicities in childhood cancer survivors: a review
E Clemens, ALF van der Kooi, L Broer, E van Dulmen-den Broeder, ...
Critical reviews in oncology/hematology 126, 154-167, 2018
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20